Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18318155 | 0.80 | BRD4 (0.38) | SYKCHRNA7 | |
| SCHEMBL18317140 | 0.79 | BRD4 (0.37) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16896811 | 0.78 | BRD4 (0.39) | — | |
| SCHEMBL18378608 | 0.78 | BRD4 (0.53) | PDE4B | |
| SCHEMBL18317398 | 0.77 | SYK (0.39) | SYKAURKBINCENPPDE4APDE4B | |
| SCHEMBL16896777 | 0.70 | GRIN1 (0.44) | SYKAURKBINCENPGRIN1GRIN2B | |
| SCHEMBL28204625 | 0.69 | SIRT1 (0.44) | — | |
| SCHEMBL18377960 | 0.69 | BRD4 (0.47) | PDE4B | |
| SCHEMBL20357659 | 0.65 | GRIN1 (0.40) | SYKAURKBINCENPPDE4APDE4B | |
| SCHEMBL16896880 | 0.65 | SYK (0.43) | SYKAURKBINCENPCHRNA7ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | SYK 3294/4885AURKB 2908/4885INCENP 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.